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Adults receiving heterologous COVID-19 immunisa-
tion with mRNA (Comirnaty) or adenoviral-vector 
(Vaxzevria) vaccines had higher reactogenicity rates 
and sought medical attention more often after two 
doses than homologous schedules. Reactogenicity 
was higher among ≤ 50 than > 50 year-olds, women and 
those with prior symptomatic/confirmed COVID-19. 
Adults receiving heterologous schedules on clinical 
advice after severe first-dose reactions had lower reac-
togenicity after dose 2 following Vaxzevria/Comirnaty 
(93.4%; 95% confidence interval: 90.5–98.1 vs 48% 
(41.0–57.7) but not Comirnaty/Vaxzevria (91.7%; 
(77.5–98.2 vs 75.0% (57.8–87.9).
Concerns about vaccine-induced thrombosis and throm-
bocytopenia syndrome (VITTs) following vaccination 
with (coronavirus disease) COVID-19 adenoviral vector 
vaccines has led to several countries recommending an 
mRNA vaccine for the second dose in younger adults 
who had been given an adenoviral vector vaccine for 
their first dose [1-4]. A clinical trial in England (COM-
COV) reported that heterologous schedules using 
mRNA-based Comirnaty (BNT162b2, BioNTech-Pfizer, 
Mainz, Germany/New York, United States) hereafter 
referred to as BNT, and adenovirus vector Vaxrevia 
(ChAdOx1/nCoV-19, AstraZeneca, Cambridge, United 
Kingdom), hereafter ChAd, COVID-19 vaccines after a 
4-week interval were associated with increased reac-
togenicity after the booster dose compared with their 
homologous counterparts, although none required 
hospitalisation [5].
Here we report on the real-world effects of heterolo-
gous prime-boost COVID-19 vaccination following the 
UK extended schedule of up to 12 weeks between 
doses.
Recruitment and participation
We used the National Immunisation Management 
System (NIMS) database to identify adults aged 18–75 
years recorded as having received a heterologous 
prime-boost schedule in England. We identified 26,779 
adults with a heterologous schedule between 29 March 
2021 and 01 June 2021, initially in London, the South 
East and East of England but later extended nationally. 
In addition, 10,000 adults who received a homologous 
prime-boost schedule on 01 June 2021 in England were 
identified through NIMS on 08 June 2021 [6]. Of these, 
7,484 individuals who were recorded as receiving their 
second dose in the previous 21 days and had provided 
a mobile phone number were texted a link to an online 
survey using SnapSurvey. 1,549 individuals accessed 
the online survey, 1,397 completed the questionnaire 
and 1,313 were included in the analysis which gave a 
response rate of 18.7% (Figure 1). Statistical analysis 
was performed using STATA/SE v.15.1 and graphs cre-
ated in RStudio [7]. 
The median age of those who had ChAd/BNT was 
49 (interquartile range (IQR): 38–59) years, 76.4% 
(437/572) were women and 90.0% (515/572) were 
white; for BNT/ChAd this was 56 (IQR: 44–64), 64.7% 
(108/167) and 88.6% (148/167) respectively. This com-
pared with 52 (IQR: 46–56) years, 61.2% (282/461) 
women and 86.6% (399/461) white for participants 
receiving ChAd/ChAd and 51 (IQR: 34–60), 71.7 (81/113) 
and 77.9% (88/113), respectively, for BNT/BNT recipi-
ents (Supplementary material 2). A higher propor-
tion of participants had ChAd than BNT as their first 
dose because of vaccine supply in England at the time 
(Supplementary material 2).
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Heterologous vs homologous schedules
The median time between doses for homologous vs 
heterologous schedules was 69 (range: 65–77) days 
and 76 (range: 67–85) days, respectively. Among pre-
viously uninfected participants (886/1,313; 67.5%), 
ChAd/ChAd recipients had significantly higher reac-
togenicity following their first dose than second dose 
(63.8%; 95% confidence interval (CI): 57.9−69.3 vs 
33.5%; 95% CI: 28.0−39.2), while BNT/BNT recipi-
ents had similar reactogenicity following both 
doses (33.3%; 95% CI: 23.4−44.5 vs 33.3%; 95% CI: 
23.4−44.5) (Supplementary material 3). Having prior 
COVID-19 symptoms (300/1,313; 22.8%) or confirmed 
COVID-19 (127/1,313; 9.7%) was generally associated 
with higher reactogenicity after the first dose for both 
vaccine brands, but particularly among those receiving 
BNT first. (Supplementary material 3 and 6). (Table 1).
After the second vaccine dose, previously uninfected 
adults in both heterologous vaccination groups had sig-
nificantly higher reactogenicity than their homologous 
counterparts, with similar rates among those receiving 
ChAd/BNT (54.4%; 95% CI: 49.4–59.5) and BNT/ChAd 
(55.2%; 95% CI: 46.1–64.1) compared with ChAd/ChAd 
(33.5%; 95% CI: 28.0–39.2) or BNT/BNT (33.3%; 95% 
CI: 23.4–44.5). Similar trends were observed among 
Figure 1
Flow diagram of recruitment and participation of individuals into study on reactogenicity in adults after heterologous 
compared to homologous prime-boost COVID-19 vaccination, 29 March−1 June 2021, England
26,779 adults who were identified as having had a 
heterologous prime-boost schedule were identified on 






7,484 adults with available mobile number 
contacted via SMS
1,549 adults accessed the online SnapSurvey
1,313 were included in the final analysis
n=152 not included in analysis due to incomplete information
n=84 not included in analysis due to replying ‘Not known’ when asked 
about prior COVID-19 symptoms
BNT: Comirnaty (BNT162b2, BioNTech-Pfizer, Mainz, Germany/New York, United States); ChAd: Vaxrevia (ChAdOx1/nCoV-19, AstraZeneca, 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































previously symptomatic and confirmed COVID-19 
cohorts (Supplementary material 3 and 6).
Age and sex
Reactogenicity was generally higher in ≤ 50 year-olds 
compared with > 50 year-olds for both doses across 
immunisation schedules, including after the second 
dose in those receiving heterologous compared with 
homologous schedules, although only significant for 
BNT/ChAd 76.3% (95% CI: 59.8–88.6) in ≤ 50 year-
olds vs 46.0% (95% CI: 35.2–57.0) in > 50 year-olds 
(Supplementary material 4 and 6). Reactogenicity was 
higher in women than men for both doses across immu-
nisation schedules (Supplementary material 5 and 6).
Schedule change because of severe 
reactogenicity
The most common reason for receiving a heterolo-
gous schedule was following clinical advice because 
of severe reactogenicity after the first dose (290/739, 
39.2%). In this cohort, reactogenicity after the second 
dose was significantly lower than the first dose for 
ChAd/BNT (93.4%; 95% CI: 90.5–98.1 vs 48%; 95% CI: 
1.0–57.7) but not BNT/ChAd (91.7%; 95% CI: 77.5–98.2 
vs 75.0%; 95% CI: 57.8–87.9). (Table 2).
Other reasons for receiving a heterologous schedule 
included supply issues, individuals requesting a dif-
ferent vaccine, receiving a different vaccine by mistake 
or other reasons including family history of clotting or 
recently pregnant. In this cohort, too, reactogenicity 
was higher in those receiving a heterologous compared 
with homologous schedules (Table 3).
Severity of reactions
In this real-world setting, 20.1% (265/1,313) participants 
required medical attention i.e. emergency department 
or hospitalisation, after their first dose; 32 for severe 
allergic reaction (1 ChAd/ChAd, 18 ChAd/BNT, 12 BNT/
ChAd, 1 BNT/BNT) including 10 with anaphylaxis, 28 
because of clotting events (ChAd/BNT) and 205 for 
other reasons including dizziness, fever, rash, dysp-
noea, limb swelling, chest pain, loss of vision, abdomi-
nal pain and nausea. Most participants with symptoms 
following either dose of vaccine, reported onset within 
48 hours post vaccination.
After the second dose, 8.1% (106/1,313) individuals 
overall required medical attention, including 55 who 
reported requiring medical attention after the first 
dose, with a higher proportion after a heterologous 
schedule. This was significant for ChAd/BNT (9.6%; 
Table 2
Number of participants who completed a heterologous schedule following clinical advise after a severe reaction to the first 
dose, with no previous symptoms of COVID-19 or confirmed infection who reported local and systemic symptoms after 















n % (95%CI) n % (95%CI) n % (95%CI) n %(95%CI)
Systemic
Fever 90 59.2 (52.6–68.7) 13 36.1 (20.8–53.8) 16 10.8 (6.3–17.0) 11 30.6 (16.3–48.1)
Chills 88 57.9 (51.1–67.4) 13 36.1 (20.8–53.8) 29 19.1 (13.5–26.9) 17 47.2 (30.4–64.5)
Headache 105 69.1 (61.1–76.3) 16 44.4 (28.0–61.9) 42 27.6 (21.3–36.4) 19 52.8 (35.5–69.6)
Unwell 115 75.6 (70.1–84.1) 21 58.3 (40.8–74.5) 38 25 (18.9–33.5) 17 47.2 (30.4–64.5)
Tiredness 108 71.1 (65.1–79.9) 20 55.6 (38.1–72.1) 39 25.7 (19.5–34.2) 20 55.6 (38.1–72.1)
Joint pain 86 56.6 (49.7–66.2) 15 41.7 (25.5–59.2) 20 13.2 (8.5–20.1) 14 38.9 (23.1–56.5)
Nausea 58 38.2 (31.3–47.5) 10 28.0 (14.2–45.2) 12 7.9 (4.3–13.7) 5 13.9 (4.7–29.5)
Local
Pain 80 52.6 (45.7–62.3) 21 58.3 (40.8–74.5) 46 30.3 (23.7–39.2) 16 44.4 (28.0–61.9)
Tenderness 69 45.4 (38.4–55.0) 20 55.6 (38.1–72.1) 43 28.3 (21.9–37.1) 17 47.2 (30.4–64.5)
Itch 17 11.2 (6.8–17.6) 5 13.9 (4.7–29.5) 8 5.3 (2.4–10.4) 1 2.8 (0.1–14.5)
Redness 32 21.1 (83.8–94.2) 6 16.7 (6.4–32.8) 11 7.2 (3.8–12.9) 6 16.7 (6.4–32.8)
Total
Systemic 133 87.5 (52.5–68.7) 24 66.7 (49.0–81.4) 63 41.5 (34.5–50.1) 25 69.4 (51.9–83.7)
Local 90 59.2 (90.5–98.1) 26 72.2 (54.8–85.8) 57 37.5 (30.6–46.9) 19 52.8 (35.5–69.6)
Overall 141 93.4 (90.5–98.1) 33 91.7 (77.5–98.2) 73 48.0 (41.0–57.7) 27 75.0 (57.8–87.9)
Medical attention 93 61.2 (53.0–69.0) 17 47.2 (30.4–64.5) 10 6.6 (3.2-11.8)) 7 19.4 (8.2–36.0)
BNT: Comirnaty (BNT162b2, BioNTech-Pfizer, Mainz, Germany/New York, United States); ChAd: Vaxrevia (ChAdOx1/nCoV-19, AstraZeneca, 
Cambridge, United Kingdom).





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Flow diagram of participants with neither previous symptoms of COVID-19 nor confirmed infection who reported severe 
reactions (Grades 3 or 4) for their second dose of the vaccine by those that reported severe reactions after their first dose 
and those that reported non-severe reactions (Grades 0–2) after their first dose by vaccination schedule
677 participants 
had ChAd for their 
dose 1
46% (309/677) had a 
non-severe reaction to 
dose 1
n = 186 had ChAd for 
their 2nd dose 
4% (8/186) had a severe 
reaction to 
dose 2
17% (21/123) had a 
severe reaction to dose 2
22% (22/101) had a 
severe reaction to dose 2 
30% (79/267) had a 
severe reaction to
dose 2
29% (26/89)  had a 
severe reaction to dose 2
10% (7/70) had a severe 
reaction to
dose 2
47% (17/36)  had a severe 
reaction to dose 2
43% (6/14)  had a severe 
reaction to 
dose 2
n = 123 had BNT for their 
2nd dose
n = 101 had ChAd for 
their 2nd dose 
n = 267 had BNT for their 
2nd dose
54% (368/677) had a 
severe reaction to dose 1
76% (159/209) had a 
non-severe reaction to 
dose 1
24% (50/209) had a 
severe 
reaction to dose 1
209 participants 
had BNT for their 
dose 1
n = 89 had ChAd for 
their 2nd dose 
n = 70 had BNT for their 
2nd dose
n = 36 had ChAd for 
their 2nd dose 
n = 14 had BNT for their 
2nd dose
BNT: Comirnaty (BNT162b2, BioNTech-Pfizer, Mainz, Germany/New York, United States); ChAd: Vaxrevia (ChAdOx1/nCoV-19, AstraZeneca, 
Cambridge, United Kingdom).
Grade 0 = No symptoms, Grade 1 = Mild – easily tolerated with no limitation on normal activity, Grade 2 = Moderate – some limitation of daily 
activity, Grade 3 = Severe – unable to perform normal daily activity and Grade 4 = Emergency department or hospital admission required [5].
7www.eurosurveillance.org
95% CI: 7.3-12.3) compared with ChAd/ChAd (2.8%; 
1.5–4.7), as well as BNT/ChAd (18.6%; 95% CI: 13.0-
25.3) compared with BNT/BNT (6.2%; 95% CI: 2.1–10.5) 
(Table 1). Of those who received a heterologous sched-
ule because of severe reactogenicity after the first 
dose, observations were similar, as were observations 
for those receiving heterologous schedules for other 
reasons, albeit non-significant.
A high proportion (29.7%, 124/418) of individuals with 
severe reaction after dose 1 reported a severe reaction 
again to dose 2, irrespective of their vaccine schedule; 
this proportion was highest for BNT/ChAd. In those 
who reporting no, mild or moderate reactions follow-
ing dose 1, both heterologous cohorts were more likely 
to report severe symptoms following dose 2: ChAd/
BNT (17.1%; 95% CI: 10.9–24.9) vs ChAd/ChAd (4.3%; 
95% CI: 1.9–8.3) and BNT/ChAd (29.1%; 95% CI: 20.1–
39.8) vs BNT/BNT (10.0%; 95% CI: 4.1–19.5) (Figure 2, 
Supplementary material 7). 
Ethical approval
Public Health England has legal permission, provided 
by Regulation 3 of The Health Service (Control of Patient 
Information) Regulations 2002, to process patient con-
fidential information for national surveillance of com-
municable diseases and as such, individual patient 
consent is not required to access records. Individual 
patient consent was obtained by those who completed 
the questionnaire.
Discussion
COVID-19 vaccines have been deployed at scale with 
great success in many countries, but most of the 
global population remains unvaccinated [8]. In Europe, 
most vaccinated individuals have received mRNA or 
adenoviral-vector vaccines. For two-dose schedules, 
individuals are recommended to receive the same vac-
cine brand because of a lack of data on heterologous 
schedules. For some, however, it may be necessary to 
offer a different type of vaccine for their second dose if, 
for example, they experienced severe anaphylaxis after 
their first dose. Given the global demand for COVID-19 
vaccines and potential interruptions in supply, vac-
cine shortages may lead to policies recommending a 
heterologous vaccine schedule to provide more rapid 
protection, especially in the context of new variants, 
where one dose may provide only partial protection [9].
Following national implementation of COVID-19 vac-
cines in England, we found that previously-uninfected 
individuals who received heterologous prime-boost 
schedules were 2.4 times (27.8% vs. 11.6%) more likely 
to report severe reactogenicity, including increased 
requirement for medical attention, after their sec-
ond dose than those receiving homologous sched-
ules. These findings were irrespective of the reason 
for receiving a heterologous schedule. Reactogenicity 
rates were higher in younger adults, women and 
after the first dose of ChAd in any schedule. Those 
experiencing severe reactions after their first dose, 
irrespective of the vaccine type, were more than twice 
as likely to experience a severe reaction after the sec-
ond dose compared to those reporting a no or a mild-
to-moderate reaction after their first dose (29.7% vs. 
13.3%). Our findings suggest that adults who have a 
severe reaction to their first dose should be advised 
that their risk of a severe reaction after their second 
dose will be higher with a heterologous schedule than 
a homologous schedule. Therefore, completion with 
the same vaccine brand should be considered unless 
there is clear evidence of anaphylaxis or other con-
traindications such as VITTs.
Our study is consistent with existing trial data report-
ing increased reactogenicity after ChAd prime but not 
with data reporting increased reactogenicity after BNT/
BNT boost [10,11]. It is also consistent with the COM-
COV study reporting increased reactogenicity following 
either heterologous schedule using a 4-week interval 
in healthy individuals [5]. Our real-world data in indi-
viduals receiving the UK-recommended 8–12 week 
extended schedule included a higher proportion of 
women, under 50 year-olds and at least 10% of partici-
pants with prior COVID-19. All these factors may have 
contributed to the higher proportion of people report-
ing severe reactions or requiring medical attention. 
This contrasts with multiple studies in Germany that 
reported little difference in reactogenicity between 
homologous and heterologous schedules [12-14]. While 
these studies were based on similar extended sched-
ules for heterologous doses, none included a BNT/
ChAd schedule. One study compared reactogenicity 
after ChAd/BNT with both homologous schedules [12], 
while others used BNT/BNT for comparison [13,14]. A 
Spanish clinical trial also reported mild reactogenicity 
overall following an extended ChAd/BNT schedule [15], 
but did not have a control arm, instead comparing reac-
togenicity to non-contemporaneous clinical trial data 
of homologous ChAd and BNT schedules [10,11]. Choice 
of controls, demographics including age, sex and 
prior infection may account for some of the observed 
differences.
The strength of our study is the use of real-world data 
to assess reactogenicity and need for medical atten-
tion after different COVID-19 vaccines and schedules. 
Our findings are, however, only applicable to heterolo-
gous immunisation with mRNA and adenoviral vector 
vaccines. Other potential limitations include recruit-
ment bias towards those with more severe reactions 
and recall bias because participants completed the 
questionnaire after their second dose. We also relied 
on participants reporting COVID-19 symptoms and 
diagnosis before vaccination. These potential biases 
would, however, have been equivalent across the dif-
ferent schedules.
Emerging immunogenicity studies indicate robust 
immune responses after heterologous immunisation 
in animal models [16], and increased antibody titres, 
cellular responses and neutralising activity against 
8 www.eurosurveillance.org
variants-of-concern in adults receiving ChAd/BNT [12-
14]. If confirmed in further studies, the benefits of 
better and potentially longer protection following het-
erologous schedules will need to be carefully assessed 
against increased reactogenicity as we have reported 
here. These findings will also have implications for 
considerations on the needs of future boosting doses.
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